Abstract: (1) Background: Colorectal cancer (CRC) is the third most common malignancy and the second leading cause of cancer deaths worldwide. It often diagnosed at advanced stages, and with increasing incidence at younger generation. CRC poses a heavy financial burden and a huge public health challenge nowadays. Lipoproteins and serum lipids may have an influence on carcinogenesis by making oxidative stress, inflammation, and insulin resistance. Dyslipidemia plays a potential role in the risk of CRC. The purpose of this study is to use nationally representative samples to determine epidemiologic characteristics of CRC in the Taiwanese population, and to evaluate the associations between baseline levels of lipid profile and their effect on risk of colorectal cancer (CRC) comprehensively and quantitatively. The control of dyslipidemia in primary and secondary prevention may reduce the disease burden of CRC. (2) Methods: This is a nationwide long-term community-based prospective cohort study. Data were retrieved from the nationwide population-based Taiwanese Survey on Hypertension, Hyperglycemia and Hyperlipidemia (TwSHHH). Variables were estimated by the Cox proportional hazards model which was then further adjusted for age. We also calculated the relative ratios (RRs) of CRC for joint categories of serum cholesterol, triglyceride (TG), low-density lipoproteins cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) level, and to examine their combined effect and statistical interactions. (3) Results: Male, age, waist circumference, diabetes mellitus (DM), high TG, high cholesterol level, smoking history, and metabolic syndrome were proved to increase the risk of CRC. In addition, DM patients with a TG level ≥150 mg/dL and cholesterol level ≥180 mg/dL had a 4.118-fold higher risk of CRC as compared with a TG level <150 mg/dL and cholesterol level <180 mg/dL, which was a significant difference (95% CI, 1.061–15.975; p = 0.0407). (4) Conclusions: Patients with DM should control TG and cholesterol level through diet, exercise, or taking medications more aggressively, not only for preventing cardiovascular disease, but also for first prevention of CRC. The study can be valuable for the clinicians and policy makers to implement more precisely goals about dyslipidemia management.

Keywords: hypertriglyceridemia; colorectal cancer; diabetes mellitus
1. Introduction

Colorectal cancer (CRC) is the second most common cause of cancer death worldwide and the third leading cancer diagnosed in the United States [1]. There are an estimated 1.93 million new CRC cases diagnosed, and 0.94 million CRC-caused deaths in 2020 worldwide. The global new CRC cases are predicted to reach 3.2 million in 2040 [2,3]. In Taiwan between 2013 and 2016, CRC was the first leading cancer for males and second in females [4]. CRC has increased incidence in younger generations, while it is often diagnosed at advanced clinical stages [5,6]. In 2017, CRC is the 36th leading cause of disease burden globally, and is the fourth leading cause of cancer burden, behind only lung cancer, liver cancer, and stomach cancer [7]. In the absence of screening, lifetime CRC-related costs of $7.286 million per 1000 50-year-olds [8]. CRC still poses a heavy financial burden and a huge public health challenge nowadays. As Taiwan has been Westernized over the past decades, the mortality rate from diseases including CRC has increased gradually for both males and females since 1971 [9]. CRC is considered primarily a “lifestyle” disease. Associated factors including age, gender, genetics, obesity, low physical activity, high animal fat diets, smoking, and alcohol consumption are considered to be potential risk factors [10]. Earlier epidemiological studies have reported a great variation in the relationship between blood lipid levels and CRC. In a large-scale cohort study in Sweden, the authors analyzed the association between serum cholesterol levels and the risks of CRC in male patients and found a positive relative risk of 1.65 among men with cholesterol levels $\geq 276$ mg/dL [11]. Other studies have claimed that increased blood cholesterol levels elevate the risk of CRC and do not have any protective effect on its occurrence or progression [12–14]. This finding suggests that high blood cholesterol levels may independently increase the risk of CRC. However, in the Framingham cohort, cholesterol levels less than 190 mg/dL were associated with a significantly increased risk of CRC [15]. Furthermore, one study failed to show any association between cholesterol levels and cancer [16].

Dyslipidemia is recognized as a prominent risk factor for cardiovascular diseases such as atherosclerosis [17]. Its prevalence is gradually increasing and is a leading cause of morbidity and mortality globally. In addition, the literature presented that lipoproteins and serum lipids may influence carcinogenesis by making oxidative stress, inflammation, and insulin resistance [18,19]. An American College of Cardiology report has reported that 39% of the global population has higher cholesterol levels, and more than one-half of those individuals lived in higher-income countries [20]. From 2002 to 2010, the prevalence of dyslipidemia increased from 18.6% to 33.97% [21]. In Taiwan from 1996 to 2006, dyslipidemia adolescent prevalence significantly escalated from 13% to 22.3% [22]. In adults, the prevalence rates of hypercholesterolemia, hypertriglyceridemia, an elevated low-density lipoprotein-cholesterol (LDL-C) level, and a low high-density lipoprotein-cholesterol (HDL-C) level for men and women were 53.3% and 48.2%, 29.3%, and 13.7%, 50.7% and 37.9%, and 47.4% and 53%, respectively [23]. Dyslipidemia remains undertreated despite screening tests being readily accessible. Previous studies have reported adults with high dyslipidemia prevalence rates but low awareness and management rates [24,25]. A 2013 study in Korea has shown the prevalence of dyslipidemia was 16.58% in middle-aged adults, but the diagnosis and treatment rates are only 11.9% [26]. Statin is one kind of medication for dyslipidemia treatment; however, 10% to 30% of patients never filled out their first statin prescriptions [27]. In addition, roughly 50% of patients discontinued statin therapy within their first year, with discontinuation rates ranging as high as $\geq 75\%$ at two years [28], as reported in previous literature. Since there are no symptoms or complications presented during the early stage of dyslipidemia, most patients usually do not have enough knowledge and would not treat it appropriately. However, if dyslipidemia is one of the risk factors for CRC, more aggressive dyslipidemia control is very important for the primary prevention of CRC to lower the disease burden.

Previous studies on the association between CRC and dyslipidemia were mainly focused on cholesterol, with a few studies considering the separate effects of triglyceride (TG), LDL-C, and HDL-C. There are conflicting results with a few studies have discovered...
an increased risk of CRC with high TG or cholesterol concentrations [29,30], other studies identifying no association or reverse effect [31,32], and only a few data of HDL and LDL associated with risk of CRC [33,34]. Further clarification and establishment should be made for a comprehensive and quantitative assessment of the association between dyslipidemia and CRC.

CRC is not only a significant problem in clinical practice but also a critical challenge for public health. To establish prevention guidelines, we aim to (1) investigate whether dyslipidemia is a risk factor of CRC, (2) evaluate the associations between baseline levels of cholesterol, TG, LDL-C, HDL-C, and (3) to analyze their combined effect on the risk of CRC. The results of this study can be valuable for clinicians and policymakers to implement more precisely the goal of dyslipidemia management. The control of dyslipidemia in primary and secondary prevention may reduce the disease burden of CRC.

2. Materials and Methods

2.1. Study Population

The data are from the Nationwide Taiwanese Survey on Hypertension, Hyperglycemia, and Hyperlipidemia (TwSHHH), conducted in 2002 [35]. The TwSHHH utilized subjects from the National Health Interview Survey (NHIS), conducted in 2001 [35] (NHIS conducted in 2001). The NHIS used a multi-stage, stratified, clustering sampling system that comprised a total of 26,685 non-institutionalized Taiwan residents from 6592 households in 1648 communities. We randomly selected 3296 households from the NHIS sampled Household Registration List in each stratum [36]. A total of 7578 (73.6% attendance rate) of 10,292 eligible subjects enrolled in the TwSHHH, but a total of 6600 adults were included in this analysis. Written informed consent was obtained from all participants in the TwSHHH. If participants had (1) missing data, and (2) age less than 30 and greater than or equal to 80 years of age, they were excluded from the first screening. Further exclusion criteria continued if participants had CRC before the enrollment, whose identification code in follow-up was lost, or either had a newly diagnosed CRC within one year after enrollment. In total, 4764 (2255 male and 2509 female) participants were analyzed in this study with 93 incident CRC, according to Figure 1. The protocols for the TwSHHH were approved by the Institutional Review Board at the Bureau of Health Promotion, Department of Health, Executive Yuan in Taiwan.

2.2. Data Collection

Sociodemographic characteristics, including age, sex, educational level, and menopausal status were noted during a home visit. Menopause was defined as free of menstruation for at least one year, irrespective of its causes. Anthropometrical data were measured at baseline, including body mass index (BMI), and waist circumferences (WC). BMI was expressed as body weight (kg) divided by squared body height (m²). WC was measured to the nearest 0.1 cm, as recommended by the World Health Organization [37]. Participants who either smoked or drank alcohol at least three times a week for at least half a year were defined and recorded as habitual smokers or drinkers.

Blood pressure was measured in a sitting position for the right arm after resting for five to ten minutes. Two readings were taken, 30 s apart. A third measurement was made if the first two differed by more than 10 mmHg. The average of the two closest readings was used. Hypertension was defined as (1) having an average systolic blood pressure (SBP) ≥ 140 mmHg; (2) having an average diastolic blood pressure (DBP) ≥ 90 mmHg; or (3) having a self-reported history of hypertension. Participants were instructed to fast for ≥8 h before blood sampling. Fasting plasma glucose (FPG) (glucose oxidase method) and TG (Bucolo method) were measured using an automated system (Vitros 550/750, Ortho-Clinical Diagnostics Inc., Johnson and Johnson Company, Rochester, NY, USA). Cholesterol, LDL-C, and HDL-C were measured using high-performance liquid chromatography (EPA-2, Helena, MT, USA). Diabetes mellitus (DM) was defined as (1) being diagnosed by a physician; or (2) being on oral anti-diabetic agents or insulin treatment; or
(3) having FPG $\geq 126$ mg/dL. Metabolic syndrome was defined by Adult Treatment Panel III criteria modified for Asians [38] as at least three of the risk factors: (1) WC measurement of $\geq 80$ cm for women or $\geq 90$ for men (2) TG $\geq 150$ mg/dL (3) HDL-C $<50$ mg/dL for women or $<40$ mg/dL for men, (4) blood pressure $\geq 130/85$ mmHg, and/or (5) fasting blood sugar $\geq 100$ mg/dL.

2.2. Data Collection

Sociodemographic characteristics, including age, sex, educational level, and menopausal status were noted during a home visit. Menopause was defined as free of menstruation for at least one year, irrespective of its causes. Anthropometrical data were measured at baseline, including body mass index (BMI), and waist circumferences (WC). BMI was expressed as body weight (kg) divided by squared body height (m$^2$). WC was measured to the nearest 0.1 cm, as recommended by the World Health Organization [37].

Participants who either smoked or drank alcohol at least three times a week for at least half a year were defined and recorded as habitual smokers or drinkers. Blood pressure was measured in a sitting position for the right arm after resting for five to ten minutes. Two readings were taken, 30 s apart. A third measurement was made if the first two differed by more than 10 mmHg. The average of the two closest readings was used. Hypertension was defined as (1) having an average systolic blood pressure (SBP) $\geq 140$ mmHg; (2) having an average diastolic blood pressure (DBP) $\geq 90$ mmHg; or (3) having a self-reported history of hypertension. Participants were instructed to fast for $\geq 8$ h before blood sampling. Fasting plasma glucose (FPG) (glucose oxidase method) and TG (Bucolo method) were measured using an automated system (Vitros 550/750, Ortho-Clinical Diagnostics Inc., Johnson and Johnson Company, Rochester, NY, USA).

4764 participants entered final analysis with 93 incident colorectal cancer

**Figure 1.** Flow of study participants in long-term follow-up study on colorectal cancer.

2.3. Statistical Analysis

Person-years of follow-up for each subject were determined from the date of enrollment to the date of the diagnosis of newly developed CRC, the date of death, or on 31 December 2018, whichever was first. Incidence rates of CRC were calculated by dividing the number of incident cases by the number of person-years of follow-up. For analysis, age were classified into three groups: $\leq 45$ years, 46–54 years, and $\geq 55$ years; serum cholesterol levels were classified into two groups: $<180$ mg/dL and $\geq 180$ mg/dL; TG classified into two groups: $<150$ mg/dL and $\geq 150$ mg/dL; LDL-C classified into three groups: $<110$ mg/dL, 110–129 mg/dL, and $\geq 130$ mg/dL; HDL-C classified into two groups: Male $> 40$ mg/dL and Female $> 50$ mg/dL, Male $\leq 40$ mg/dL and Female $\leq 50$ mg/dL; BMI into three groups: $<24$ kg/m$^2$, 24–27 kg/m$^2$, and $\geq 27$ kg/m$^2$, according to definition that overweight and obesity are defined as BMI $\geq 24$ and $\geq 27$ kg/m$^2$ in Taiwan, respectively [39]. WC is
divided into three groups: \( \leq 85 \text{ cm}, 86–95 \text{ cm}, \text{ and } >95 \text{ cm} \), based on median, 95%, and 99% quantile in our database. Relative risks (RRs) and 95% confidence intervals (95% CIs) for age, gender, serum cholesterol, TG, LDL-C, HDL-C level, BMI, and WC were estimated by the Cox proportional hazards model. The following analyses were adjusted for age. We also calculated the RRs of CRC in patients with or without DM for joint categories of serum cholesterol and TG level. All statistical analyses were performed using the SAS statistical package (version 9.4; SAS Institute, Inc., Cary, NC, USA). \( p \)-values for the trends were evaluated by the two-sided test considering 0.05 as statistically significant.

3. Results

Table 1 shows the basic characteristics of the participants. There were 2255 male (47.33%) and 2509 female (52.67%) in this study. The mean age was 49.37 years. Most were \( \leq 45 \) years old adults (43.32%) and had an elementary school educational level (27.97%) or senior high school educational level (27.18%).

| Variable                  | Subject | (%)  |
|---------------------------|---------|------|
| Gender                    |         |      |
| Female                    | 2509    | 52.67|
| Male                      | 2255    | 47.33|
| Age (Years)               |         |      |
| \( \leq 45 \)             | 2064    | 43.32|
| 46–55                     | 1248    | 26.2 |
| \( \geq 55 \)             | 1452    | 30.48|
| Mean (SD)                 | 49.37   | 12.67|
| Educational level         |         |      |
| Elementary                | 1330    | 27.97|
| Illiterate                | 369     | 7.76 |
| Junior high school        | 774     | 16.28|
| Senior high school        | 1322    | 27.8 |
| College                   | 960     | 20.19|
| Missing                   | 9       |      |

Table 2 showed the risk factors associated with CRC incidence. The univariate analysis results showed that male (compared to female, crude HR = 2.119; 95% CI: 1.386–3.241), with DM (crude HR = 3.653; 95% CI: 2.264–5.895), TG \( \geq 150 \) (compared with TG < 150, crude HR = 2.047; 95% CI: 1.206–3.474), cholesterol \( \geq 180 \) (compared with cholesterol < 180, crude HR = 1.723; 95% CI: 1.111–2.671), smoking history (crude HR = 1.965; 95% CI: 1.303–2.963), menopause (crude HR = 2.536; 95% CI: 1.239–5.188) and with metabolic syndrome (crude HR = 1.590; 95% CI: 1.016–2.488) were statistically significantly associated with CRC. The age of 46 to 54 and \( \geq 55 \) were at a 2.677- and 5.53-fold risk of CRC compared with age \( \leq 45 \). WC of 86 to 95 cm and >95 cm was at a 1.585- and 2.120-fold risk of CRC compared with a WC \( \leq 85 \). After adjusting with age, male (aHR = 2.071; 95% CI: 1.354–3.168, \( p = 0.0008 \)), with DM (aHR = 2.462; 95% CI: 1.507–4.024, \( p = 0.0003 \)), TG \( \geq 150 \) (compared with <150, aHR = 1.716; 95% CI: 1.009–2.920, \( p = 0.0463 \)) and smoking history (aHR = 2.053; 95% CI: 1.361–3.095, \( p = 0.0006 \)) were still statistically significantly associated with CRC.

Figure 2 is the cumulative incidence of colorectal cancer based on gender in Taiwan. For males, the median follow-up period was 16.71 years. During the observation period, the Nelson–Aalen estimate of the cumulative incidence of male CRC was 0.00% in one year, 0.0073% in five years, 0.0173% in ten years, and 0.027% in fifteen years. For females, the median follow-up period was 16.73 years. The cumulative incidence of female CRC was 0.00% in one year, 0.0033% in five years, 0.0083% in ten years, and 0.0121% in fifteen years. The cumulative incidence of the male was significantly higher than that of the female (log-rank test \( p < 0.001 \); Figure 2).
Table 2. Risk factors associated with colon cancer incidence.

| Variables                  | Subjects | Cases | Person-Years | Incidence Rate | Crude HR (95% CI) | p-Value | AHR a (95% CI) | p-Value |
|----------------------------|----------|-------|--------------|----------------|-------------------|---------|----------------|---------|
| Total                      | 4764     | 93    | 73,812.20    | 126            |                   |         |                |         |
| Gender                     |          |       |              |                |                   |         |                |         |
| Female                     | 2509     | 33    | 39,702.86    | 83.12          | 1                 |         |                |         |
| Male                       | 2255     | 60    | 34,109.34    | 175.9          | 2.19              | 0.0005  | 2.071          | 1.354   |
| Age (year)                 |          |       |              |                |                   |         |                |         |
| <45                        | 2064     | 16    | 33,877.66    | 47.23          | 1                 |         |                |         |
| 46–54                      | 1248     | 25    | 19,812.68    | 126.18         | 2.67              | 0.0021  | 2.071          | 1.354   |
| ≥55                        | 1452     | 52    | 20,121.85    | 258.43         | 5.52              | <0.0001 | 2.071          | 1.354   |
| Educational level          |          |       |              |                |                   |         |                |         |
| Elementary                 | 1330     | 37    | 19,555.84    | 189.2          | 1                 |         |                |         |
| Illiterate                 | 369      | 7     | 509.56       | 137.4          | 0.73              | 0.443   | 0.497          | 0.220   |
| Junior high school         | 774      | 21    | 12,179.35    | 172.42         | 0.91              | 0.722   | 1.548          | 0.891   |
| Senior high school         | 1322     | 14    | 21,285.94    | 170.95         | 1.53              | 0.007   | 0.712          | 0.373   |
| College                    | 960      | 14    | 15,467.27    | 90.05          | 0.47              | 0.017   | 0.928          | 0.489   |
| Diabetes Mellitus          |          |       |              |                |                   |         |                |         |
| Never                      | 4323     | 71    | 67,921.49    | 104.53         | 1                 |         |                |         |
| Have                       | 437      | 22    | 5823.87      | 377.76         | 3.63              | <0.0001 | 2.462          | 1.507   |
| Hypertension               |          |       |              |                |                   |         |                |         |
| Never                      | 3568     | 64    | 56,814.56    | 112.65         | 1                 |         |                |         |
| Have                       | 1194     | 29    | 16,967.07    | 170.95         | 1.53              | 0.058   | 0.883          | 0.556   |
| Cholesterol (mg/dL)        |          |       |              |                |                   |         |                |         |
| <180                       | 2090     | 29    | 32,365.95    | 89.6           | 1                 |         |                |         |
| ≥180                       | 2672     | 64    | 41,412.84    | 154.54         | 1.73              | 0.015   | 1.396          | 0.898   |
| LDL (mg/dL)                |          |       |              |                |                   |         |                |         |
| <110                       | 1791     | 26    | 27,879.83    | 93.26          | 1                 |         |                |         |
| 110–129                    | 1433     | 32    | 22,161.75    | 144.39         | 1.54              | 0.098   | 1.307          | 0.777   |
| ≥130                       | 1538     | 35    | 23,737.21    | 147.45         | 1.52              | 0.078   | 1.156          | 0.691   |
| TG (mg/dL)                 |          |       |              |                |                   |         |                |         |
| <150                       | 3294     | 58    | 51,470.89    | 112.69         | 1                 |         |                |         |
| ≥150                       | 506      | 18    | 7798.17      | 230.82         | 2.04              | 0.0079  | 1.716          | 1.009   |
| HDL (mg/dL)                |          |       |              |                |                   |         |                |         |
| Male >40                   | 3491     | 68    | 54,569.16    | 124.61         | 1                 |         |                |         |
| Female >50                 | 1271     | 25    | 19,209.63    | 130.14         | 1.05              | 0.8422  | 1.077          | 0.681   |
| Male ≤40                   |          |       |              |                |                   |         |                |         |
| Female ≤50                 |          |       |              |                |                   |         |                |         |
| Body Mass Index (kg/m²)    |          |       |              |                |                   |         |                |         |
| <24                        | 2441     | 38    | 38,528.66    | 98.63          | 1                 |         |                |         |
| 24–27                      | 1239     | 26    | 19,135.57    | 135.74         | 1.37              | 0.203   | 1.220          | 0.740   |
| ≥27                        | 628      | 17    | 9802.24      | 173.43         | 1.75              | 0.0534  | 1.596          | 0.900   |
| Waist circumference (cm)   |          |       |              |                |                   |         |                |         |
| ≤85                        | 3025     | 48    | 47,717.51    | 100.59         | 1                 |         |                |         |
| 86–95                      | 1286     | 31    | 19,460.29    | 159.30         | 1.58              | 0.0455  | 1.215          | 0.768   |
| ≥95                        | 446      | 14    | 6577.19      | 212.86         | 2.12              | 0.0134  | 1.645          | 0.901   |
| Smoking habit              |          |       |              |                |                   |         |                |         |
| Never                      | 3383     | 53    | 53,204.58    | 99.62          | 1                 |         |                |         |
| Ever                       | 1374     | 40    | 20,490.81    | 195.21         | 1.96              | 0.0013  | 2.053          | 1.361   |
| Drinking habits            |          |       |              |                |                   |         |                |         |
| Never                      | 3426     | 65    | 52,972.80    | 122.7          | 1                 |         |                |         |
| Ever                       | 1331     | 28    | 20,722.59    | 135.12         | 1.1               | 0.6742  | 1.295          | 0.828   |
Table 2. Cont.

| Variables                     | Subjects | Cases | Person-Years | Incidence Rate | Crude HR (95% CI) | p-Value | AHR a (95% CI) | p-Value |
|-------------------------------|----------|-------|--------------|----------------|-------------------|---------|----------------|---------|
| **Menopause**                 |          |       |              |                |                   |         |                |         |
| Never                         | 1454     | 12    | 23,865.14    | 50.28          | 1                 |         |                |         |
| Ever                          | 1053     | 20    | 15,814.44    | 126.47         | 2.536 (1.239, 5.188) | 0.0108  | 1.028          | 0.324   | 3.260   | 0.9627 |
| **Metabolic syndrome**        |          |       |              |                |                   |         |                |         |
| Never                         | 3683     | 66    | 58,031.27    | 113.73         | 1                 |         |                |         |
| Have                          | 1027     | 27    | 14,989.93    | 180.12         | 1.590 (1.016, 2.488) | 0.0424  | 1.139          | 0.720   | 1.800   | 0.5786 |
| **Exercise**                  |          |       |              |                |                   |         |                |         |
| Never                         | 3635     | 66    | 56,283.23    | 117.26         | 1                 |         |                |         |
| Have                          | 1127     | 27    | 17,495.07    | 154.33         | 1.316 (0.841, 2.059) | 0.2298  | 1.017          | 0.647   | 1.598   | 0.9432 |
| **Animal fat diet**           |          |       |              |                |                   |         |                |         |
| Low                           | 2758     | 50    | 42,901.11    | 116.55         | 1                 |         |                |         |
| High                          | 2005     | 43    | 30,894.37    | 139.18         | 1.195 (0.795, 1.796) | 0.3921  | 1.168          | 0.777   | 1.757   | 0.4541 |

Abbreviations: LDL, low-density lipoprotein; TG, Triglyceride; HDL, high-density lipoprotein; a: Adjusted with age Cox proportional hazards regression.

Figure 2. Cumulative incidence of colorectal cancer based on gender.

Table 3 shows the association between the development of CRC in DM status and cholesterol levels and TG. In this analysis, we separated the participants into DM and non-DM groups, and classified cholesterol levels into two groups based on a cutoff value of 180 mg/dL and TG levels into two groups based on a cutoff value of 150 mg/dL, which was identified as shown in Table 2. We found that, in the DM group, those with a TG level ≥150 mg/dL and cholesterol level ≥180 mg/dL had a 4.118-fold higher risk of CRC as compared with a TG level <150 mg/dL and cholesterol level <180 mg/dL, which was a significant difference (95% CI, 1.061–15.975; p = 0.0407).
Table 3. Combination effects for cholesterol, triglyceride (TG) level, and colorectal cancer risk in DM and non-DM group.

|                      | DM                         | Non-DM                      |
|----------------------|-----------------------------|-----------------------------|
|                      | TG < 150 mg/dL              | TG ≥ 150 mg/dL              |
| Cholesterol          |                            |                             |
| <180 mg/dL           | 1.00 (Referent)            | 1.00 (Referent)            |
|                      | (0.137–12.820)             | (0.186–3.449)               |
| ≥180 mg/dL           | 4.118 *                    | 1.339                      |
|                      | (1.061–15.975)             | (0.751–2.388)               |

Adjusted for age, gender, diabetes mellitus comorbidity, triglyceride level, and total cholesterol level of colorectal cancer. * p = 0.005.

4. Discussion

This is a prospective cohort study based on a population of aged 30–80 years old in Taiwan. We have found that, in the DM group, TG ≥ 150 mg/dL and cholesterol levels ≥ 180 mg/dL caused a 4.118-fold increased risk of CRC as compared with TG < 150 mg/dL and cholesterol levels < 180 mg/dL, which reached statistical significance. To the best of our knowledge, this study is a long-term community-based cohort study with a nationally representative sample on the association between CRC risk and serum lipid profile. The accuracy collected from the national cancer registry database guaranteed the complete identification of incident cases of CRC. We determined epidemiologic characteristics of CRC in the Taiwanese population, including the fact that, for a DM patient, more active cholesterol and TG control were necessary for CRC prevention.

Despite the numerous studies that explored the relationship between blood lipids and CRC, they are still controversial. Several studies in the early 1980s reported an inverse association between cancer and serum cholesterol levels, but the association disappeared when excluding cases diagnosed within two years of enrollment [40–43]. Therefore, some researchers have suggested that lower serum cholesterol levels may reflect a response to early, undiagnosed cancers [15]. Conversely, a study based on incidence data from the Sweden nationwide cancer register presented an association between serum cholesterol levels and positive colorectal cancer. With a relative risk of 1.65 among those with cholesterol levels ≥276 mg/dL, this was statistically significant for CRC in males [11]. In the Swedish cohort, males with serum cholesterol levels <190 mg/dL did not have a higher risk for CRC [11].

Our findings revealed that, in the univariate analysis, cholesterol level ≥180 mg/dL had a 1.723-fold risk of CRC compared to cholesterol <180, which was consistent with several epidemiological works of literature previously [11,12,44,45]. A case-cohort Italian study revealed that elevated serum cholesterol is a risk factor for CRC mainly in men and postmenopausal women [29]. The evidence supporting that high cholesterol levels increase the risk for CRC partly comes from research on colorectal adenoma, which is well documented as the precursor lesion of cancer. A Korean study showed that the risk of adenomatous polyp increases with a rise in serum cholesterol levels. They compared participants with low cholesterol concentration (<199 mg/dL) with those with intermediate (200–249 mg/dL) and high concentrations (>250 mg/dL) and concluded that the groups had adjusted odds ratios of 1.82 and 2.44, respectively [13]. Another study further showed that higher cholesterol levels increased the likelihood of having colorectal villous adenoma [46], the type of adenoma at the highest risk for cancer development.

Statins remain the first-line treatment to manage hypercholesterolemia, and some studies revealed that they may show a protective effect on CRC as they can inhibit the cell cycle and induce apoptosis [47,48]. For hypercholesterolemia patients, taking statins may lower the risk of CRC. To our study, the overall relative risk of CRC may be underestimated.

Cholesterol in colorectal carcinogenesis may be involved in its effect on inflammation which may promote inhibit apoptosis and cellular proliferation [49,50]. Hypercholes-
terolemia is associated with oxidative stress and may play a part in cancer development [51], perhaps by altering gene expression. From the genetic perspective, the adenomatous polyposis coli (APC) gene is well recognized in regulating cellular proliferation, and its mutation plays a crucial role in initiating normal epithelium-adenomatous polyp-malignant neoplasm transformation [52]. Peroxisome proliferator-activated receptor (PPAR) is important for lipid storage and adipocyte differentiation and also is highly conveyed in the colonic epithelium [53]. In an animal model of colorectal tumors and human familial adenomatous polyposis, referred to as APC-deficient mice, Niho and their colleagues found concomitant suppression of hypercholesterolemia and intestinal polyp formation by PPARγ ligands [54]. The evidence implicates that PPARγ and the APC gene might be involved in the link between blood cholesterol and CRC, but further research on the complex genetic networks of carcinogenesis is needed to explain the widely diverse trends in CRC risk among different populations.

In our study, TG $\geq 150$ mg/dL had a 2.047- and 1.716-fold risk of CRC compared to TG $< 150$ separately, with statistical significance under univariate analysis and after adjusting age. The effect of TG on CRC is also conflicting in previous studies. Some studies showed no association [55,56]. However, there is an increasing amount of data supporting a positive association between hypertriglyceridemia and the incidence of CRC. Borena and their colleagues discovered that RR for the top quintile compared to the bottom quintile TG of CRC were 1.16 (95% CI, 1.06–1.26) in men and 1.15 (1.05–1.27) in women [57]. Stocks and their colleagues presented that TG was significantly associated with CRC in men (RR, 1.17; 95% CI, 1.06–1.28) [58]. According to an Austria cohort study, higher TG concentrations were associated with an increased risk of CRC both in men and women (HR, 1.56; 95% CI, 1.00–2.44) [59].

Through inducing inflammation or energy supply to neoplastic cells, serum TG concentrations may be connected to CRC risk [60]. A few studies have presented that hypertriglyceridemia is associated with frequent infections and inflammation [61,62]. From the energy supply point of view, insulin resistance represents the most plausible link between obesity and higher TG, which may lead to increased lipolysis, adiposopathy, and release of free fatty acid (FFA) into the circulation [63–65]. The lipolytic pathway plays a part in the progression of CRC [66], and adipose triglyceride lipase (ATGL) was important in the rate-limiting enzymes involved in lipolysis [67]. TG metabolism is instigated by ATGL through hydrolyzing TG into FFA and diacylglycerol. ATGL-mediated lipolysis releases a large amount of FFA, which is an important adaptation to the high proliferation rates of tumor cells [68]. Yin and their colleagues presented that increased ATGL positively correlates with CRC while the knockdown of ATGL inhibits the proliferation and promotes the apoptosis of CRC cells in vitro [69].

Our study displayed that DM is an important risk factor for CRC. Many Type 2 DM patients also had hypertriglyceridemia. These mechanisms are linked to insulin resistance and hyperglycemia, which resulted in the overproduction of TG-rich lipoproteins from the liver [70]. In our study, DM patients with a TG $\geq 150$ mg/dL and cholesterol level $\geq 180$ mg/dL had a 4.118-fold higher risk of CRC as compared with a TG level $< 150$ mg/dL and cholesterol level $< 180$ mg/dL and with significant difference (95% CI, 1.061–15.975; $p = 0.0407$). Therefore, patients with DM should control TG and cholesterol levels through diet, exercise, or taking medications more aggressively, or the risk of CRC will increase.

This study comes with strengths and limitations. The main advantage of the study is that this is a prospective cohort design. This avoided inverse causation bias, which was unlikely to occur, with nationally representative samples and with a sufficient follow-up period. We determined the epidemiologic characteristics of CRC in the Taiwanese population. Moreover, all biochemical data including lipid biomarkers were measured using the standardized and validated blood biochemistry methods with strict quality controls in a single central laboratory, thereby minimizing any measurement errors. However, since this cohort included only Taiwanese, some studies showed that there may be ethnic differences in the etiology and biology of CRC between Asians and non-Asians. Therefore,
the generalization of the study findings to other ethnicities should be reconfirmed. It is hard to evaluate newly detected DM or dyslipidemia that could change during the follow-up period. Therefore, we might have underestimated the relative risk of CRC associated with DM and dyslipidemia. Some potential confounders such as medication use and family history were not measured.

5. Conclusions

This is an important finding for CRC prevention, especially for DM and dyslipidemia patients. It has been confirmed that the combined effect of dyslipidemia and DM will lead to an increased risk of CRC. From the point of view of preventive medications, maintaining a stable weight and blood cholesterol, TG in the appropriate range during middle adulthood is important to prevent CRC. Both the government of Taiwan and physicians can use the findings of this study as a reference when formulating screening strategies for CRC in Taiwan and also to reduce the economic burden of CRC on the national health expenditure.

Author Contributions: Conceptualization, S.-H.H.; methodology, S.-H.H.; software, S.-H.H. and Y.-C.C.; validation, S.-H.H., D.-K.S., Y.-C.C., C.-K.L., C.-A.S., M.C.; formal analysis, S.-H.H., D.-K.S., Y.-C.C., C.-K.L., C.-A.S. and M.C.; investigation, S.-H.H., D.-K.S., Y.-C.C., C.-K.L., C.-A.S. and M.C.; resources, S.-H.H. and Y.-C.C.; data curation, S.-H.H., D.-K.S., Y.-C.C. and C.-K.L.; writing—original draft preparation, S.-H.H.; writing—review and editing, S.-H.H., D.-K.S., Y.-C.C., C.-K.L., C.-A.S. and M.C.; visualization, S.-H.H.; supervision, C.-K.L., C.-A.S. and M.C.; project administration, C.-A.S. and M.C. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Fu Jen Catholic University (A0110183).

Institutional Review Board Statement: The protocols for the TwSHHH were approved by the Institutional Review Board at the Bureau of Health Promotion, Department of Health, Executive Yuan in Taiwan.

Informed Consent Statement: Written informed consent has been obtained from the patient(s) to publish this paper if applicable.

Data Availability Statement: Data are available from the Health and Welfare Data Science Center, HWDC. Due to legal restrictions imposed by the government of Taiwan in relation to the “Personal Information Protection Act”, the data cannot be made publicly available. Requests for data can be sent as a formal proposal to the https://dep.mohw.gov.tw/DOS/lp-2503-113-3-20.html.

Acknowledgments: The authors would like to express thanks to the Fu Jen University Foundation.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Bray, F.; Ferlay, J. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [CrossRef] [PubMed]
2. International Agency for Research on Cancer (IARC). Globocan 2018: Cancer Fact Sheets—Colorectal Cancer. 2018. Available online: http://gco.iarc.fr/today/data/factsheets/cancers/10_8_9-Colorectum-fact-sheet.pdf (accessed on 17 October 2018).
3. Yue, X.; Pengfei, X. Global colorectal cancer burden in 2020 and projections to 2040. Transl. Oncol. 2021, 14, 101174. [CrossRef] [PubMed]
4. Huang, Y.C.; Chen, Y.H. Cancer incidence characteristic evolution based on the National Cancer Registry in Taiwan. J. Oncol. 2020, 2020, 1408793. [CrossRef] [PubMed]
5. Keum, N.; Giovannucci, E. Global burden of colorectal cancer: Emerging trends, risk factors and prevention strategies. Nat. Rev. Gastroenterol. Hepatol. 2019, 16, 713–732. [CrossRef] [PubMed]
6. Campos, F.G. Colorectal cancer in young adults: A difficult challenge. World J. Gastroenterol. 2017, 23, 5041–5044. [CrossRef] [PubMed]
7. Guren, M.G. The global challenge of colorectal cancer. Lancet Gastroenterol. Hepatol. 2019, 4, 894–895. [CrossRef]
8. Peterse, E.F.P.; Meester, R.G.S. Comparing the Cost-Effectiveness of Innovative Colorectal Cancer Screening Tests. J. Natl. Cancer Inst. 2021, 113, 154–161. [CrossRef]
9. Chen, C.J.; You, S.L. Cancer epidemiology and control in Taiwan: A brief review. Jpn. J. Clin. Oncol. 2002, 32, 566–581. [CrossRef]
10. Lee, C.H.; Cheng, S.C. The risk factors affecting survival in colorectal cancer in Taiwan. Iran. J. Public Health 2018, 47, 519–530.
11. Tornberg, S.A.; Holm, L.E. Risks of cancer of the colon and rectum in relation to serum cholesterol and beta-lipoprotein. N. Engl. J. Med. 1986, 315, 1629–1633. [CrossRef]
12. Mamtani, R.; Lewis, J.D. Disentangling the association between statins, cholesterol, and colorectal cancer: A nested case-control study. *PLoS Med.* 2016, 13, e1002007. [CrossRef] [PubMed]

13. Park, S.K.; Joo, J.S. Association of serum lipids and glucose with the risk of colorectal adenomatous polyp in men: A case-control study in Korea. *J. Korean Med. Sci.* 2000, 15, 690–695. [CrossRef] [PubMed]

14. Rodriguez-Broadbent, H.; Law, P.J. Mendelian randomisation implicates hyperlipidaemia as risk factor for colorectal cancer. *Int. J. Cancer* 2017, 140, 2701–2708. [CrossRef] [PubMed]

15. Sorlie, P.D.; Fienleib, M. The serum cholesterol-cancer relationship: An analysis of time trends in the Framingham study. *J. Natl. Cancer Inst.* 1982, 69, 989–996. [PubMed]

16. Yaari, S.; Goldbourt, E.-Z. Associations of serum high density lipoprotein and total cholesterol with total, cardiovascular, and cancer mortality in a 7-year prospective study of 10,000 men. *Lancet* 1981, 1, 1011–1015. [CrossRef]

17. American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2019. *Diabetes Care* 2019, 42 (Suppl. 1), S103–S123. [CrossRef]

18. Long, J.; Zhang, C.-J. Lipid metabolism and carcinogenesis, cancer development. *Am. J. Cancer Res.*

19. Ackerman, D.; Simon, M.C. Hypoxia, lipids, and cancer: Surviving the harsh tumor microenvironment.

20. Laslett, L.J.; Alagona, P., Jr. The worldwide environment of cardiovascular disease: Prevalence, diagnosis, therapy, and policy issues: A report from the American College of Cardiology. *J. Am. Coll. Cardiol.* 2012, 60, S1–S49. [CrossRef]

21. Xinghua, Y.; Chaonan, X. Risk prediction model of dyslipidaemia over a 5-year period based on the Taiwan MJ health check-up longitudinal database. *Lipids Health Dis.* 2018, 17, 259.

22. Kuo, P.; Syu, J.T. Prevalence and trend of dyslipidaemia from 1996 to 2006 among normal and overweight adolescents in Taiwan. *BMJ Open* 2014, 4, e003800. [CrossRef]

23. Cheng, K.C.; Chen, Y.L. Prevalence of dyslipidaemia in patients receiving health checkups: A hospital-based study. *Cholesterol 2011*, 2011, 314234. [CrossRef] [PubMed]

24. Opoku, S.; Gan, Y. Awareness, treatment, control, and determinants of dyslipidemia among adults in China. *Sci. Rep.* 2021, 11, 10056. [CrossRef] [PubMed]

25. Kim, S.J.; Kwon, O.D. Impact of a family history of cardiovascular disease on prevalence, awareness, treatment, control of dyslipidemia, and healthy behaviors: Findings from the Korea National Health and Nutrition Examination Survey. *PLoS ONE* 2021, 16, e0254907. [CrossRef] [PubMed]

26. Boo, S.; Yoon, Y.J. Evaluating the prevalence, awareness, and control of hypertension, diabetes, and dyslipidemia in Korea using the NHIS-NSC database: A cross-sectional analysis. *Medicine ( Baltim )* 2018, 97, e13713. [CrossRef]

27. Cheetham, T.C.; Niu, F. Primary nonadherence to statin medications in a managed care organization. *J. Manag. Care Pharm.* 2013, 19, 367–373. [CrossRef]

28. Krähenbühl, S.; Pavik-Mezzour, I. Unmet needs in LDL-C lowering: When statins won’t do! *Eur. J. Cardiovasc. Prev.* 2014, 21, 144–151. [CrossRef]

29. Inoue, M.; Noda, M. Impact of metabolic factors on subsequent cancer risk: Results from a large-scale population-based cohort study in Japan. *Eur. J. Cancer Prev.* 2009, 18, 240–247. [CrossRef]

30. Strohmaier, S.; Edlinger, M. Total serum cholesterol and cancer incidence in the Metabolic syndrome and Cancer Project (Me-Can). *PLoS ONE* 2013, 8, e54242. [CrossRef] [PubMed]

31. van Duijnhoven, F.J.; Bueno-De-Mesquita, H.B. Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition. *Cancer Causes Control.* 2011, 20, 1094–1102. [CrossRef]

32. Ahamed, R.L.; Schmitz, K.H. The metabolic syndrome and risk of incident colorectal cancer. *Cancer* 2006, 107, 28–36. [CrossRef] [PubMed]

33. Bowers, K.; Albanes, D. A prospective study of anthropometric and clinical measurements associated with insulin resistance syndrome and colorectal cancer in male smokers. *Am. J. Epidemiol.* 2006, 164, 652–664. [CrossRef] [PubMed]

34. Shih, Y.T.; Hung, Y.T. The design, contents, operation and the characteristics of the respondents of the 2001 National Health Interview Survey in Taiwan. *Taiwan J. Public Health* 2003, 22, 419–430.

35. Hwang, L.C.; Bai, C.H. Prevalence of obesity and metabolic syndrome in Taiwan. *J. Formos. Med. Assoc.* 2006, 105, 626–635. [CrossRef]

36. World Health Organization. *Physical Status: The Use and Interpretation of Anthropometry, Report of a WHO Expert Committee,* WHO: Geneva, Switzerland, 1995; Available online: https://www.who.int/publications/i/item/9241208546 (accessed on 20 December 2019).

37. Lin, C.C.; Liu, C.S.; Lai, M.M.; Li, C.I.; Chen, C.C.; Chang, P.C.; Lin, W.-Y.; Lee, Y.-D.; Lin, T.; Li, T.-C. Metabolic syndrome in a Taiwanese metropolitan adult population. *BMC Public Health* 2007, 7, 239. [CrossRef] [PubMed]

38. Huang, K.C. Obesity and its related diseases in Taiwan. *Obes. Rev.* 2008, 9 (Suppl. 1), 32–34. [CrossRef] [PubMed]

39. Kagan, A.; McGee, D.L. Serum cholesterol and mortality in a Japanese-American population: The Honolulu Heart program. *Am. J. Epidemiol.* 1981, 114, 11–20. [CrossRef]

40. Circulating cholesterol level and risk of death from cancer in men aged 40 to 69 years: Experience of an international collaborative group. *JAMA* 1982, 248, 2853–2859. [CrossRef]
42. Morris, D.L.; Borhani, N.O. Serum cholesterol and cancer in the hypertension detection and follow-up program. Cancer 1983, 52, 1754–1759. [CrossRef]
43. Rose, G.; Shipley, M.J. Plasma lipids and mortality: A source of error. Lancet 1980, 315, 523–526. [CrossRef]
44. Radisaukas, R.; Kuzmickiene, I. Hypertension, serum lipids and cancer risk: A review of epidemiological evidence. Medicina 2016, 52, 89–98. [CrossRef] [PubMed]
45. Murai, T. Cholesterol lowering: Role in cancer prevention and treatment. Biol. Chem. 2015, 396, 1–11. [CrossRef] [PubMed]
46. Houghton, J.; Lardieri, G.G. Effect of cholesterol levels on villous histology in colonic adenomas. Dig. Dis. Sci. 2000, 45, 896–899. [CrossRef]
47. Lee, J.W.; You, N.Y. Statin use and site-specific risk of colorectal cancer in individuals with hypercholesterolemia from the National Health Insurance Service-National Health Screening Cohort (NHIS-HEALS). Nutr. Metab. Cardiovasc. Dis. 2019, 29, 701–709. [CrossRef]
48. Ye, P.; Xi, Y. Linking obesity with colorectal cancer: Epidemiology and mechanistic insights. Cancer Causes Control 2014, 25, 237–249. [CrossRef]
49. Ye, P.; Xi, Y. Linking obesity with colorectal cancer: Epidemiology and mechanistic insights. Cancers 2020, 12, 1408. [CrossRef] [PubMed]
50. Sekharam, M.; Nasir, A. Insulin-like growth factor 1 receptor activates c-SRC and modifies transformation and motility of colorectal cancer in vitro. Anticancer Res. 2003, 23, 1517–1524. [PubMed]
51. Rouillier, P.; Senesse, P. Dietary patterns and the adenomacarcinoma sequence of colorectal cancer. Eur. J. Nutr. 2005, 44, 311–318. [CrossRef]
52. Zhang, L.; Theodoropoulos, P.C. Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer. Sci. Transl. Med. 2016, 8, 361ra140. [CrossRef]
53. Liang, X.; Fan, X. Peroxisome proliferators-activated receptor gamma polymorphisms and colorectal cancer risk. J. Cancer Res. Ther. 2018, 14, S306–S310. [CrossRef] [PubMed]
54. Niho, N.; Takahashi, M. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. Cancer Res. 2003, 63, 6090–6095.
55. Ashbeck, E.L.; Jacobs, E.T. Components of metabolic syndrome and metachronous colorectal neoplasia. Cancer Epidemiol. Biomark. Prev. 2009, 18, 1134–1143. [CrossRef] [PubMed]
56. Liang, X.; Fan, X. Peroxisome proliferators-activated receptor gamma polymorphisms and colorectal cancer risk. Cancer Epidemiol. Biomark. Prev. 2003, 12, 412–418.
57. Borena, W.; Stocks, T. Serum triglycerides and cancer risk in the metabolic syndrome and cancer (Me-Can) collaborative study. Cancer Causes Control 2011, 22, 291–299. [CrossRef]
58. Stocks, T.; Lukanova, A. Metabolic factors and the risk of colorectal cancer in 580,000 men and women in the metabolic syndrome and cancer project (Me-Can). Cancer 2011, 117, 2398–2407. [CrossRef]
59. Ulmer, H.; Borena, W. Serum triglyceride concentrations and cancer risk in a large cohort study in Austria. Br. J. Cancer 2009, 101, 1202–1206. [CrossRef]
60. McKeown-Eyssen, G. Epidemiology of colorectal cancer revisited: Are serum triglycerides and/or plasma glucose associated with risk? Cancer Epidemiol. Biomark. Prev. 1994, 3, 687–695.
61. Kundu, J.K.; Suri, Y.J. Inflammation: Gearing the journey to cancer. Mutat. Res. 2008, 659, 15–30. [CrossRef]
62. Esteve, E.; Ricart, W. Dyslipidemia and inflammation: An evolutionary conserved mechanism. Clin. Nutr. 2005, 24, 16–31. [CrossRef]
63. Vekic, J.; Zeljkovic, A. Obesity and dyslipidemia. Metabolism 2019, 92, 71–81. [CrossRef] [PubMed]
64. Paglialisotti, M.J.; Kim, P.Y. Endoplasmic reticulum stress in obesity and obesity-related disorders: An expanded view. Metabolism 2016, 65, 1238–1246. [CrossRef] [PubMed]
65. Klopf, B.; Eltz, J.W. Dyslipidemia in obesity: Mechanisms and potential targets. Nutrients 2013, 5, 1218–1240. [CrossRef] [PubMed]
66. Beloribi-Djefalha, S.; Vasseur, S. Lipid metabolic reprogramming in cancer cells. Oncogenesis 2016, 5, e189. [CrossRef]
67. Rolando, V.; Luca, D.L. Hints on ATGL implications in cancer: Beyond bioenergetic clues. Cell Death Dis. 2018, 9, 316.
68. Zimmermann, R.; Strauss, J.G. Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science 2004, 306, 1383–1386. [CrossRef]
69. Yin, H.; Li, W. Adipose triglyceride lipase promotes the proliferation of colorectal cancer cells via enhancing the lipolytic pathway. J. Cell. Mol. Med. 2021, 25, 3963–3975. [CrossRef]
70. Hirano, T. Pathophysiology of Diabetic Dyslipidemia. J. Atheroscler. Thromb. 2018, 25, 771–782. [CrossRef]